📊 XRAY Key Takeaways
Is DENTSPLY SIRONA Inc. (XRAY) a Good Investment?
Dentsply Sirona is unprofitable with negative operating income of -35.0M, negative free cash flow of -12.0M, and an interest coverage ratio of -1.9x indicating inability to service 2.0B in debt from operations. Combined with 3.0% YoY revenue decline and only 190.0M cash against substantial leverage, the company faces unsustainable financial stress requiring immediate operational turnaround or restructuring.
Why Buy DENTSPLY SIRONA Inc. Stock? XRAY Key Strengths
- Strong gross margin of 48.5% demonstrates underlying product competitiveness and pricing power
- Current ratio of 1.53x provides near-term working capital cushion
- EPS improved 33% YoY despite ongoing losses, showing some operational progress
XRAY Stock Risks: DENTSPLY SIRONA Inc. Investment Risks
- Negative free cash flow of -12.0M indicates cash burn and inability to self-fund operations or debt service
- Interest coverage of -1.9x is critically negative, company cannot cover debt obligations from earnings
- Revenue declining 3.0% YoY combined with -4.0% operating margin threatens viability without major turnaround
- High leverage with 1.52x debt-to-equity ratio and only 190.0M liquidity against 2.0B long-term debt
- Quick ratio of 0.98x below 1.0 signals potential working capital stress
Key Metrics to Watch
- Operating income path to positive territory and sustainability
- Free cash flow inflection point and burn rate trajectory
- Revenue stabilization and return to growth momentum
- Interest coverage ratio and debt refinancing capacity
- Cash balance depletion rate and covenant compliance status
DENTSPLY SIRONA Inc. (XRAY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
DENTSPLY SIRONA Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
XRAY Profit Margin, ROE & Profitability Analysis
XRAY vs Healthcare Sector: How DENTSPLY SIRONA Inc. Compares
How DENTSPLY SIRONA Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DENTSPLY SIRONA Inc. Stock Overvalued? XRAY Valuation Analysis 2026
Based on fundamental analysis, DENTSPLY SIRONA Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DENTSPLY SIRONA Inc. Balance Sheet: XRAY Debt, Cash & Liquidity
XRAY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: DENTSPLY SIRONA Inc.'s revenue has remained relatively flat over the 5-year period, with a 7% decline. The most recent EPS of $-0.62 indicates the company is currently unprofitable.
XRAY Revenue Growth, EPS Growth & YoY Performance
XRAY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $879.0M | -$10.0M | $-0.05 |
| Q3 2025 | $904.0M | -$427.0M | $-2.14 |
| Q2 2025 | $936.0M | -$4.0M | $-0.02 |
| Q1 2025 | $879.0M | $18.0M | $0.09 |
| Q3 2024 | $947.0M | -$199.0M | $-0.94 |
| Q2 2024 | $984.0M | -$4.0M | $-0.02 |
| Q1 2024 | $953.0M | $18.0M | $-0.09 |
| Q3 2023 | $947.0M | -$199.0M | $-0.94 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DENTSPLY SIRONA Inc. Dividends, Buybacks & Capital Allocation
XRAY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for DENTSPLY SIRONA Inc. (CIK: 0000818479)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XRAY
What is the AI rating for XRAY?
DENTSPLY SIRONA Inc. (XRAY) has an AI rating of STRONG SELL with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XRAY's key strengths?
Claude: Strong gross margin of 48.5% demonstrates underlying product competitiveness and pricing power. Current ratio of 1.53x provides near-term working capital cushion.
What are the risks of investing in XRAY?
Claude: Negative free cash flow of -12.0M indicates cash burn and inability to self-fund operations or debt service. Interest coverage of -1.9x is critically negative, company cannot cover debt obligations from earnings.
What is XRAY's revenue and growth?
DENTSPLY SIRONA Inc. reported revenue of $880.0M.
Does XRAY pay dividends?
DENTSPLY SIRONA Inc. pays dividends, with $32.0M distributed to shareholders in the trailing twelve months.
Where can I find XRAY SEC filings?
Official SEC filings for DENTSPLY SIRONA Inc. (CIK: 0000818479) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XRAY's EPS?
DENTSPLY SIRONA Inc. has a diluted EPS of $-0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XRAY a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, DENTSPLY SIRONA Inc. has a STRONG SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XRAY stock overvalued or undervalued?
Valuation metrics for XRAY: ROE of -0.8% (sector avg: 15%), net margin of -1.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XRAY stock in 2026?
Our dual AI analysis gives DENTSPLY SIRONA Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XRAY's free cash flow?
DENTSPLY SIRONA Inc.'s operating cash flow is $40.0M, with capital expenditures of $52.0M. FCF margin is -1.4%.
How does XRAY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1.1% (avg: 12%), ROE -0.8% (avg: 15%), current ratio 1.53 (avg: 2).
Is DENTSPLY SIRONA Inc. carrying too much debt?
XRAY has a debt-to-equity ratio of 1.52x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.53 suggests adequate short-term liquidity.